Rob DeWig, VP of Healthcare Sales at Inmar, touches on how access to 25% of benchmarking data from national pharmacy claims ...

Ryan Quigley, CEO of Inizio, explains how AI, personalized medicine, and GLP 1s are shaping commercialization trends.

CDC vaccine advisers delay Hepatitis B schedule changes while recommending separate vaccines for measles, mumps, rubella, and ...

Biogen expands its drug delivery solutions by acquiring Alcyone Therapeutics, enhancing patient-centered therapies with the ...

The FDA has expanded the indication of Incyte’s Opzelura (ruxolitinib) cream to include children aged two to 11 years with ...

VectorY Therapeutics partners with Shape Therapeutics to advance innovative therapies for neurodegenerative diseases using ...

Jason O’Neill, author of 'The Secrets of Successful Drug Launches' and former Dendreon CEO, details how products having an insufficient relative advantage, enter the market too late, or are ...

Rob DeWig, VP of Healthcare Sales at Inmar, touches on looming DSCSA enforcement and the impact of Inmar's reconciliation tools.

Our five-year plan is to continue to do what we do really well and be that scaled, large, trusted partner that can help pharma and biopharma bring their new medicines and innovations into the market.

HOSP focuses on advocacy, collaboration, and best practice sharing to enhance health system specialty pharmacies and improve ...

Merck’s executive director, operations lead, global medical affairs and outcomes research discusses how data is helping to ...